# Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Source: https://onco.cc/trials/nct06498635/  
OnCo record `nct06498635` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of durvalumab in lung cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial is a phase 3, randomised interventional study registered as NCT06498635 by National Cancer Institute (NCI), with a registry enrolment figure of 306 participants, started 2025-04-01 and due to reach its primary completion in 2039-07-15. Interventions recorded: Biospecimen Collection; Computed Tomography; Durvalumab; Patient Observation; Questionnaire Administration. Conditions listed: Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: "* Participants must have histologically or cytological confirmed diagnosis of clinical stage II-IIIB (excluding clinical N3 disease) non-small cell lung cancer (NSCLC)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06498635
- Phase: 3
- Setting: Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in The AdjuvanT Setting (INSIGHT)
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 306

## Sources

- ClinicalTrials.gov NCT06498635: https://clinicaltrials.gov/study/NCT06498635

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06498635.json